etoposide has been researched along with Papillomavirus Infections in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, KM; Chang, SJ; Chen, TC; Chen, YT; Chuang, YJ; Lai, ZY; Yeo, HY | 1 |
| Byun, MR; Choi, JW; Kim, YR; Lee, B; Lee, JK | 1 |
| Anderson, RA; Li, W | 1 |
| Donaldson, MM; Dornan, ES; Fisk, JC; King, LE; Melendy, T; Morgan, IM | 1 |
| Abrego-Pérez, G; Castañeda-Hernandez, G; Cervera, E; Coll, M; García-López, P; Hernández-Pájaro, AI; Meneses, A; Mohar-Betancourt, A; Reyes-Vermot, L; Torres, MA | 1 |
| Daibata, M; Hatakeyama, N; Hiroi, M; Kamioka, M; Miyoshi, I; Nemoto, Y; Taguchi, H | 1 |
1 trial(s) available for etoposide and Papillomavirus Infections
| Article | Year |
|---|---|
The systemic absorption of etoposide after intravaginal administration in patients with cervical intraepithelial lesions associated with human papillomavirus infection.
Topics: Absorption; Administration, Intravaginal; Adult; Antineoplastic Agents, Phytogenic; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Electrochemistry; Etoposide; Female; Humans; Indicators and Reagents; Middle Aged; Papillomavirus Infections; Prospective Studies | 2006 |
5 other study(ies) available for etoposide and Papillomavirus Infections
| Article | Year |
|---|---|
PI3K inhibitor enhances the cytotoxic response to etoposide and cisplatin in a newly established neuroendocrine cervical carcinoma cell line.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers; Carcinoma, Neuroendocrine; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Disease Models, Animal; DNA Damage; Drug Synergism; Etoposide; Female; Humans; Mice; Papillomavirus Infections; Phosphoinositide-3 Kinase Inhibitors; Uterine Cervical Neoplasms; Xenograft Model Antitumor Assays | 2017 |
Evaluation of pemetrexed and etoposide as therapeutic regimens for human papillomavirus-positive oral and oropharyngeal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Screening Assays, Antitumor; Etoposide; Humans; Mouth Neoplasms; Oncogene Proteins, Viral; Papillomaviridae; Papillomavirus Infections; Pemetrexed; Pharyngeal Neoplasms | 2018 |
Star-PAP controls HPV E6 regulation of p53 and sensitizes cells to VP-16.
Topics: Antineoplastic Agents, Phytogenic; Cell Proliferation; DNA-Binding Proteins; Etoposide; Female; Gene Expression; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Nucleotidyltransferases; Oncogene Proteins, Viral; Papillomavirus Infections; Polyadenylation; Polynucleotide Adenylyltransferase; RNA, Messenger; Tumor Suppressor Protein p53; Uterine Cervical Neoplasms | 2014 |
Human papillomavirus E1 and E2 mediated DNA replication is not arrested by DNA damage signalling.
Topics: Antigens, Viral, Tumor; Cell Line; DNA Breaks, Double-Stranded; DNA Damage; DNA Replication; DNA-Binding Proteins; DNA, Viral; Etoposide; Female; Genomic Instability; Human papillomavirus 11; Humans; Papillomaviridae; Papillomavirus Infections; Signal Transduction; Uterine Cervical Neoplasms; Viral Proteins; Virus Integration; Virus Replication | 2010 |
Detection of human herpesvirus 6 and JC virus in progressive multifocal leukoencephalopathy complicating follicular lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain; Cyclophosphamide; DNA, Viral; Doxorubicin; Etoposide; Fatal Outcome; Female; Herpesviridae Infections; Herpesvirus 6, Human; Humans; Immunity, Cellular; Immunocompromised Host; JC Virus; Leukoencephalopathy, Progressive Multifocal; Lymphoma, Follicular; Magnetic Resonance Imaging; Mitoxantrone; Nitrosourea Compounds; Papillomavirus Infections; Piperazines; Polymerase Chain Reaction; Prednisolone; Recurrence; Salvage Therapy; Vincristine; Vindesine; Virus Activation | 2001 |